Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 2, 1999, Pages 129-136

  Van Milligen De Wit, A W Marc ^a,c   Kuiper, Hilde ^b   Camoglio, Luisa ^a   Van Bracht, Jeroen ^a   Jones, E Anthony ^a   Tytgat, Guido N J ^a   Van Deventer, Sander J H ^a  

^a Dept of Gastroenterol and Hepatol ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Red Cross Hospital Den Haag   (Netherlands)

Author keywords

Cytokines; Immunomodulation; Liver histology; Liver immunohistochemistry; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ANTIGEN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LIVER FIBROSIS; MALE; ORAL DRUG ADMINISTRATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0032908642     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199902000-00013     Document Type: Article

References (50)

1. 1 Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis, Hepatology 1989; 4:430-436.
2. 2 Van Milligen de Wit AWM, Van Deventer SJH, Tytgat GNJ. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90:893-900.
3. 3 Mistilis SP, Skyring AP, Goulston SJ. Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Aust Ann Med 1965; 14:286-294.
4. 4 Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicin in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 1:57-61.
5. 5 Javett SL. Azathioprine in primary sclerosing cholangitis. Lancet 1971; i:810-811.
6. 6 LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95:1036-1042.
7. 7 Polter DE, Gruhl V, Eigenbrodt EH, Combes B. Beneficial effect of cholestyramine in sclerosing cholangitis. Gastroenterology 1989; 79:326-333.
8. 8 Wiesner RH, Steiner B, LaRusso NF, Lindor KD, Baldus WP. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis [Abstract]. Hepatology 1991; 14:63A.
9. 9 Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse mothotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106:494-499.
10. 10 Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995; 108:1199-1203.
11. 11 Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh RA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-1290.
12. 12 Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149-1156.
13. 13 Poupon RE, Poupon R, Balkau B and the UDCA Study Group. Ursodiol for the longterm treatment of primary biliary cirrhosis. N Engl J Med 1994; 330:1342-1347.
14. 14 Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-766.
15. 15 Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinico-pathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985; 88:108-114.
16. 16 Chazouilleres O, Poupon R, Capron J-P, Metman, E-H, Dhumeaux D, Armouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11:120-123.
17. 17 O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G, Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14:838-847.
18. 18 Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16:707-714.
19. 19 Stichl A, Walker S, Steihl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20:57-64.
20. 20 Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336:691-695.
21. 21 Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11:11-17.
22. 22 Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
23. 23 Pajkrt D, Camoglio L, Tiel-van Buul CM, De Bruin K, Cutler DL, Affrime MB, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia. J Immunol 1997; 158:3971-3977.
24. 24 Kimmings AN, Van Deventer SJH, Jansen J, Mevissen M, Gouma DJ, et al. Depression of the cell mediated response in human obstructive jaundice: possible causative factors and the effect of biliary stenting. In: Inflammatory Aspects of Obstructive Jaundice: Pathogenesis and Treatment Strategies. Thesis, University of Amsterdam, 1996; pp. 87-103.
25. 25 Lindor KD, Wiosner RH, Katzmann JA, LaRusso NF, Beaver SJ. Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci 1987; 32:720-725.
26. 26 Magrin S, Nouri-Aria KT, Donaldson PT, Wilkinson ML, Portmann BC, Williams R, et al. The relationship between HLA-DR3 and T-cell regulation of immunoglobulin production in primary sclerosing cholangitis. Clin Immunol Immunopathol 1989; 50:205-212.
27. 27 Kilby AE, Krawitt EL, Albertini RJ, Chastenay BF, John A. Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study. Dig Dis Sci 1991; 36:1213-1216.
28. 28 Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21:870-877.
29. 29 Poupon RE, Balkau B, Eschwege E, Poupon R, the UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324:1548-1554.
30. 30 Mehal WZ, Snook JA, Rudenski A, Kay JDS, Chapman RW, et al. Procollagen III peptide as an indicator of hepatic fibrogenesis in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1992; 4:937-941.
31. 31 Olsson R, Hagerstrand I, Broome U, Danielsson A, Jarnerot G, Loof L, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995; 48:933-935.
32. 32 Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995; 23:283-289.
33. 33 Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic acid and chenodeoxycholic acid on small intestinal absorption of bile acids. Gastroenterology 1990; 98:424-428.
34. 34 Heuman DM, Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993; 104:1865-1870.
35. 35 Heuman DM, Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106:1333-1341.
36. 36 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15.
37. 37 Lo SK, Chapman RW, Dooley JS, Fleming KA. Aberrant HLA-DR expression by bile duct epithelium in primary sclerosing cholangitis is down-regulated by ursodeoxycholic acid [Abstract]. Gastroenterology 1993; 4:A943.
38. 38 Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K, Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol 1991; 86:1194-1199.
39. 39 Calmus Y, Arvieux C, Gane P, Boucher E, Nordinger B, Rouger P, et al. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992; 102:1371-1377.
40. 40 Chapman RW, Kelly PMA, Heryet A, Jewell DP, Fleming KA. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988; 29:422-427.
41. 41 Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO'D. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol 1987; 40:879-884.
42. 42 Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 1995; 36:604-609.
43. 43 Adams DH, Hubscher SG, Shaw J, Johnson GD, Babbs C, Rothlein R, et al. Increased expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1991; 14:426-431.
44. 44 Broome U, Hultcrantz R, Scheynius A. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primary sclerosing cholangitis and primary biliary cirrhosis. Scand J Gastroenterol 1993; 28:126-130.
45. 45 Keane RM, Gadecz TR, Munster AM, Birmingham W, Winchurch RA. Impairment of human lymphocyte function by bile salts. Surgery 1983; 95:439-443.
46. 46 Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16:358-364.
47. 47 Calmus Y, Guechot J, Podevin P, Bonnefis M-T, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor production by monocytes. Hepatology 1992; 16:719-723.
48. 48 Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103:617-621.
49. 49 Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993; 18:165-172.
50. 50 Hechtman DH, Cybulski MI, Fuchs HJ, Baker JB, Gimbrone MA Jr. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991; 147:883-892.